REG - Arecor Therapeutics - Result of AGM

Arecor TherapeuticsAnnouncement

Yesterday 14:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260528:nRSb1038Ga&default-theme=true

RNS Number : 1038G  Arecor Therapeutics PLC  28 May 2026

Arecor Therapeutics plc

("Arecor" or the "Company")

 

Result of AGM

Cambridge, UK, 28 May 2026: Arecor Therapeutics plc (AIM: AREC), a clinical
stage biotech company developing superior therapeutics that can reduce
treatment burden and improve outcomes for people living with diabetes, obesity
and other cardiometabolic diseases, announces that at its Annual General
Meeting held earlier today, all resolutions were passed.

The full text of each resolution was included in the Company's Notice of
Annual General Meeting made available on the Company's website
(https://arecor.com/investor-centre/shareholder-information/) .

The number of proxy votes cast for and against each of the resolutions
proposed, and the number of proxy votes withheld are shown in the table below.

The Board notes that 31.82% of votes were against Resolution 5. The Board
confirms that it will consult and continue to engage with shareholders to
understand and discuss their concerns with respect to this resolution.

 

 Resolution                                                                       Votes       %        Votes against  %       Votes withheld

 for
 Resolution 1                                                                     17,588,351  100%     0              0%      0

 To receive the directors' report, the consolidated financial statements and
 the auditors' report for the year ended 31 December 2025
 Resolution 2                                                                     16,756,524  95.30%   827,227        4.70%   4,600

 To approve the directors' remuneration report as set out on pages 31 to 36 in
 the annual report for the year ended 31 December 2025
 Resolution 3                                                                     16,756,524  95.30%   827,227        4.70%   4,600

 To approve the director's remuneration policy as set out on pages 32 to 34 in
 the annual report for the year ended 31 December 2025
 Resolution 4                                                                     16,756,524  100.00%  0              0.00%   831,827

 To re-elect Sarah Howell as a Director of the Company in accordance with the
 articles
 Resolution 5                                                                     11,952,304  68.18%   5,576,941      31.82%  59,106

 To re-elect Andrew Richards as a Director of the company in accordance with
 the articles
 Resolution 6                                                                     16,756,524  100.00%  0              0.00%   831,827

 To re-elect Sam Fazeli as a Director of the Company in accordance with the
 articles
 Resolution 7                                                                     16,756,524  95.30%   827,227        4.70%   4,600

 To re-elect Jeremy Morgan as a Director of the Company in accordance with the
 articles
 Resolution 8                                                                     16,756,524  100.00%  0              0.00%   831,827

 To re-elect Simon Ormiston as a Director of the Company in accordance with the
 articles
 Resolution 9                                                                     16,756,524  100.00%  0              0.00%   831,827

 To re-elect David Ellam as a Director of the Company in accordance with the
 articles
 Resolution 10                                                                    17,575,001  99.93%   11,500         0.07%   1,850

 To re-appoint PKF Littlejohn LLP as auditors of the Company
 Resolution 11                                                                    17,588,351  100.00%  0              0.00%   0

 To authorise the Directors to agree the auditors' remuneration
 Resolution 12                                                                    17,459,642  99.59%   71,453         0.41%   0

 To authorise the allotment of shares
 Resolution 13                                                                    17,503,110  99.53%   83,391         0.47%   1,850

 To disapply statutory pre-emption rights

 

-ENDS-

For more information, please contact:

 Arecor Therapeutics plc

Dr Sarah Howell, Chief Executive Officer

David Ellam, Chief Financial Officer            +44 (0) 1223 426060

                                                  info@arecor.com
 Singer Capital Markets Advisory LLP

(NOMAD and Broker)

 Phil Davies, James Fischer                       +44 (0) 20 7496 3000
 Vigo Consulting (Financial Communications)       +44 (0) 20 7390 0230
 Melanie Toyne-Sewell, Rozi Morris

                                                  arecor@vigoconsulting.com
 Vida Strategic Partners (US Investor Relations)  +1 (415) 675-7401

 Stephanie Diaz                                   sdiaz@vidasp.com

 

Notes to Editors

About Arecor

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company
developing superior therapeutics that can reduce treatment burden and improve
outcomes for people living with diabetes, obesity and other cardiometabolic
diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL)
ultra-rapid-acting insulin in development. Arecor has signed an initial
strategic partnership with Sequel Med Tech, a leading automated insulin
delivery (AID) system company to co-develop AT278 in combination with Sequel's
twiist™ AID system. Clinically de-risked, AT278 is designed to transform AID
systems, addressing a multi-billion dollar diabetes market. Arecor is also
developing a novel oral delivery platform for peptides with GLP-1 receptor
agonists its first validation target.

The Company is listed on AIM (AIM: AREC) and is based in Cambridge, UK. For
further details please see www.arecor.com (http://www.arecor.com/) .

Arecor® and Arestat® are registered trademarks of Arecor Limited.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGAKFBNBBKDCPB



            Copyright 2019 Regulatory News Service, all rights reserved